FarFaR - Pharmacy Repository
University of Belgrade, Faculty of Pharmacy
    • English
    • Српски
    • Српски (Serbia)
  • English 
    • English
    • Serbian (Cyrillic)
    • Serbian (Latin)
  • Login
View Item 
  •   FarFaR
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • View Item
  •   FarFaR
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

The effect of cannabinoid receptor 1 blockade on hepatic free fatty acid profile in mice with nonalcoholic fatty liver disease

Authorized Users Only
2017
Authors
Jorgačević, B
Vučević, D
Đuričić, Ivana
Šobajić, Slađana
Mladenović, Dušan
Vesković, M
Vukićević, R.J
Radosavljević, Tatjana S.
Article (Published version)
Metadata
Show full item record
Abstract
We used rimonabant to investigate the role of CB1 receptor on hepatic FFAs profile during NAFLD. Male mice C57BL/6 were divided into: control group fed with control diet 20 weeks (C; n = 6); group fed with HFD 20 weeks (HF; n = 6); group fed with control diet and treated with rimonabant after 18 weeks (R; n = 9); group fed with HFD and treated with rimonabant after 18 weeks (HFR; n = 10). Rimonabant (10 mg/kg) was administered daily to HFR and R group by oral gavage. Rimonabant decreased liver palmitic acid proportion in HFR group compared to HF group (p  lt  0.05). Liver stearic and oleic acid proportions were decreased in R group compared to control (p  lt  0.01 respectively). Rimonabant increased liver linoleic and arachidonic acid proportions in HFR group compared to HF group (p  lt  0.01 respectively). CB1 blockade may be useful in the treatment of HFD-induced NAFLD due to modulation of plasma lipid and hepatic FFA profile.
Keywords:
CB1 receptor blockade / Endocannabinoid system / Free fatty acid profile / Mice / NAFLD / Rimonabant
Source:
Chemistry and Physics of Lipids, 2017, 204, 85-93
Publisher:
  • Elsevier Ireland Ltd
Funding / projects:
  • The role of neuroendocrine-inflammatory axis in the pathogenesis of non-alcoholic fatty liver disease (RS-175015)

DOI: 10.1016/j.chemphyslip.2017.03.009

ISSN: 0009-3084

WoS: 000400530000010

Scopus: 2-s2.0-85017112176
[ Google Scholar ]
6
4
URI
https://farfar.pharmacy.bg.ac.rs/handle/123456789/2915
Collections
  • Radovi istraživača / Researchers’ publications
Institution/Community
Pharmacy
TY  - JOUR
AU  - Jorgačević, B
AU  - Vučević, D
AU  - Đuričić, Ivana
AU  - Šobajić, Slađana
AU  - Mladenović, Dušan
AU  - Vesković, M
AU  - Vukićević, R.J
AU  - Radosavljević, Tatjana S.
PY  - 2017
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2915
AB  - We used rimonabant to investigate the role of CB1 receptor on hepatic FFAs profile during NAFLD. Male mice C57BL/6 were divided into: control group fed with control diet 20 weeks (C; n = 6); group fed with HFD 20 weeks (HF; n = 6); group fed with control diet and treated with rimonabant after 18 weeks (R; n = 9); group fed with HFD and treated with rimonabant after 18 weeks (HFR; n = 10). Rimonabant (10 mg/kg) was administered daily to HFR and R group by oral gavage. Rimonabant decreased liver palmitic acid proportion in HFR group compared to HF group (p  lt  0.05). Liver stearic and oleic acid proportions were decreased in R group compared to control (p  lt  0.01 respectively). Rimonabant increased liver linoleic and arachidonic acid proportions in HFR group compared to HF group (p  lt  0.01 respectively). CB1 blockade may be useful in the treatment of HFD-induced NAFLD due to modulation of plasma lipid and hepatic FFA profile.
PB  - Elsevier Ireland Ltd
T2  - Chemistry and Physics of Lipids
T1  - The effect of cannabinoid receptor 1 blockade on hepatic free fatty acid profile in mice with nonalcoholic fatty liver disease
VL  - 204
SP  - 85
EP  - 93
DO  - 10.1016/j.chemphyslip.2017.03.009
ER  - 
@article{
author = "Jorgačević, B and Vučević, D and Đuričić, Ivana and Šobajić, Slađana and Mladenović, Dušan and Vesković, M and Vukićević, R.J and Radosavljević, Tatjana S.",
year = "2017",
abstract = "We used rimonabant to investigate the role of CB1 receptor on hepatic FFAs profile during NAFLD. Male mice C57BL/6 were divided into: control group fed with control diet 20 weeks (C; n = 6); group fed with HFD 20 weeks (HF; n = 6); group fed with control diet and treated with rimonabant after 18 weeks (R; n = 9); group fed with HFD and treated with rimonabant after 18 weeks (HFR; n = 10). Rimonabant (10 mg/kg) was administered daily to HFR and R group by oral gavage. Rimonabant decreased liver palmitic acid proportion in HFR group compared to HF group (p  lt  0.05). Liver stearic and oleic acid proportions were decreased in R group compared to control (p  lt  0.01 respectively). Rimonabant increased liver linoleic and arachidonic acid proportions in HFR group compared to HF group (p  lt  0.01 respectively). CB1 blockade may be useful in the treatment of HFD-induced NAFLD due to modulation of plasma lipid and hepatic FFA profile.",
publisher = "Elsevier Ireland Ltd",
journal = "Chemistry and Physics of Lipids",
title = "The effect of cannabinoid receptor 1 blockade on hepatic free fatty acid profile in mice with nonalcoholic fatty liver disease",
volume = "204",
pages = "85-93",
doi = "10.1016/j.chemphyslip.2017.03.009"
}
Jorgačević, B., Vučević, D., Đuričić, I., Šobajić, S., Mladenović, D., Vesković, M., Vukićević, R.J,& Radosavljević, T. S.. (2017). The effect of cannabinoid receptor 1 blockade on hepatic free fatty acid profile in mice with nonalcoholic fatty liver disease. in Chemistry and Physics of Lipids
Elsevier Ireland Ltd., 204, 85-93.
https://doi.org/10.1016/j.chemphyslip.2017.03.009
Jorgačević B, Vučević D, Đuričić I, Šobajić S, Mladenović D, Vesković M, Vukićević R, Radosavljević TS. The effect of cannabinoid receptor 1 blockade on hepatic free fatty acid profile in mice with nonalcoholic fatty liver disease. in Chemistry and Physics of Lipids. 2017;204:85-93.
doi:10.1016/j.chemphyslip.2017.03.009 .
Jorgačević, B, Vučević, D, Đuričić, Ivana, Šobajić, Slađana, Mladenović, Dušan, Vesković, M, Vukićević, R.J, Radosavljević, Tatjana S., "The effect of cannabinoid receptor 1 blockade on hepatic free fatty acid profile in mice with nonalcoholic fatty liver disease" in Chemistry and Physics of Lipids, 204 (2017):85-93,
https://doi.org/10.1016/j.chemphyslip.2017.03.009 . .

DSpace software copyright © 2002-2015  DuraSpace
About FarFaR - Pharmacy Repository | Send Feedback

OpenAIRERCUB
 

 

All of DSpaceCommunitiesAuthorsTitlesSubjectsThis institutionAuthorsTitlesSubjects

Statistics

View Usage Statistics

DSpace software copyright © 2002-2015  DuraSpace
About FarFaR - Pharmacy Repository | Send Feedback

OpenAIRERCUB